Contact Information
37 Westminster Buildings, Theatre Square,
Nottingham, NG1 6LG
Healthcare/Life Sciences
![Elliott Takes Big Stake in Drugmaker Catalent](http://www.nasdaqpicks.com/wp-content/uploads/2023/07/Elliott-Takes-Big-Stake-in-Drugmaker-Catalent-400x400.jpeg)
Elliott Takes Big Stake in Drugmaker Catalent
- By nasdaqpicks.com
- . 20 July 2023
The activist is pushing for a shake-up of the contract drug manufacturer’s board. Source link
![Elliott Takes Big Stake in Drugmaker Catalent](http://www.nasdaqpicks.com/wp-content/uploads/2023/07/Elliott-Takes-Big-Stake-in-Drugmaker-Catalent-400x400.jpeg)
Elliott Takes Big Stake in Drugmaker Catalent
- By nasdaqpicks.com
- . 20 July 2023
The activist is pushing for a shake-up of the contract drug manufacturer’s board. Source link
![FDA Approves First RSV Drug to Protect All Infants](http://www.nasdaqpicks.com/wp-content/uploads/2023/07/FDA-Approves-First-RSV-Drug-to-Protect-All-Infants-400x400.jpeg)
FDA Approves First RSV Drug to Protect All Infants
- By nasdaqpicks.com
- . 17 July 2023
While the virus often leads to mild, coldlike symptoms, it is the leading cause of hospitalization of infants in the U.S. Source link
![Drugs Like Ozempic Created a Gold Rush. These Drugmakers Want In.](http://www.nasdaqpicks.com/wp-content/uploads/2023/07/Drugs-Like-Ozempic-Created-a-Gold-Rush-These-Drugmakers-Want-400x400.jpeg)
Drugs Like Ozempic Created a Gold Rush. These Drugmakers Want In.
- By nasdaqpicks.com
- . 16 July 2023
Companies developing weight-loss drugs have raised or made deals valued at more than $1.4 billion since about a year ago. Source link
![Eli Lilly to Acquire Versanis Bio, Maker of Obesity Treatment](http://www.nasdaqpicks.com/wp-content/uploads/2023/07/Eli-Lilly-to-Acquire-Versanis-Bio-Maker-of-Obesity-Treatment-400x400.jpeg)
Eli Lilly to Acquire Versanis Bio, Maker of Obesity Treatment
- By nasdaqpicks.com
- . 14 July 2023
Versanis shareholders could receive as much as $1.925 billion in cash, which will consist of an upfront payment and additional payments if certain milestones are
![Roivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billion](http://www.nasdaqpicks.com/wp-content/uploads/2023/07/Roivant-in-Talks-to-Sell-Stomach-Drug-to-Roche-in-400x400.jpeg)
Roivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billion
- By nasdaqpicks.com
- . 14 July 2023
Roivant, started by presidential candidate Vivek Ramaswamy, could seal a deal in coming days. Source link
![Johnson & Johnson Sues Doctors Over Studies Linking Talc-Based Products and Cancer](http://www.nasdaqpicks.com/wp-content/uploads/2023/07/Johnson-amp-Johnson-Sues-Doctors-Over-Studies-Linking-Talc-Based-Products-400x400.jpeg)
Johnson & Johnson Sues Doctors Over Studies Linking Talc-Based Products and Cancer
- By nasdaqpicks.com
- . 14 July 2023
Company says the studies played a significant role in lawsuits over its Baby Powder and Shower to Shower products. Source link
![Roivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billion](http://www.nasdaqpicks.com/wp-content/uploads/2023/07/Roivant-in-Talks-to-Sell-Stomach-Drug-to-Roche-in-400x400.jpeg)
Roivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billion
- By nasdaqpicks.com
- . 13 July 2023
Roivant, started by presidential candidate Vivek Ramaswamy, could seal a deal in coming days Source link
![FDA Approves First Over-the-Counter Birth-Control Pill](http://www.nasdaqpicks.com/wp-content/uploads/2023/07/FDA-Approves-First-Over-the-Counter-Birth-Control-Pill-400x400.jpeg)
FDA Approves First Over-the-Counter Birth-Control Pill
- By nasdaqpicks.com
- . 13 July 2023
The Food and Drug Administration approved the first over-the-counter birth-control pill, significantly expanding access to contraception among women across the U.S. Source link
![Illumina Fined More Than $400 Million in Europe for Closing Grail Deal Early](http://www.nasdaqpicks.com/wp-content/uploads/2023/07/Illumina-Fined-More-Than-400-Million-in-Europe-for-Closing-400x400.jpeg)
Illumina Fined More Than $400 Million in Europe for Closing Grail Deal Early
- By nasdaqpicks.com
- . 12 July 2023
The European Union’s antitrust watchdog fined the company with the maximum allowable amount for wrapping up its acquisition of the cancer-test developer while the agency